1.53
-0.02(-1.29%)
Currency In USD
| Previous Close | 1.55 |
| Open | 1.61 |
| Day High | 1.86 |
| Day Low | 1.5 |
| 52-Week High | 5.17 |
| 52-Week Low | 1.05 |
| Volume | 6.27M |
| Average Volume | 1M |
| Market Cap | 165.67M |
| PE | -0.96 |
| EPS | -1.59 |
| Moving Average 50 Days | 1.49 |
| Moving Average 200 Days | 1.98 |
| Change | -0.02 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) since IPO date, it would be worth $139.09 as of July 30, 2025 at a share price of $1.53. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $676.99 as of July 30, 2025 at a share price of $1.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
GlobeNewswire Inc.
Yesterday at 8:01 PM GMT
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerabili
Aclaris Therapeutics Announces Leadership Transition
GlobeNewswire Inc.
Jul 28, 2025 12:45 PM GMT
- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
GlobeNewswire Inc.
Jun 30, 2025 1:31 PM GMT
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company ha